The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCAR-T 2023 | Lymphoma CAR and bispecific updates
In this captivating session chaired by Loretta Nastoupil, MD University of Texas MD Anderson Center, Houston, TX, Mazyar Shadman, MD Fred Hutchinson Cancer Research Center, Seattle, WA, and Tycel Phillips, MD, City of Hope, Duarte, CA, share the latest advances in CAR-T therapy and bispecific antibodies for lymphoma. The experts comment on CD22 CARs and third-generation CD20 CARs, and move on to the use of axicabtagene ciloleucel (axi-cel) in central nervous system (CNS) lymphoma and discuss real-world data on brexucabtagene autoleucel (brexu-cel) in mantle cell lymphoma (MCL). The experts then talk on strategies to overcome some of the limitations of autologous CAR-Ts, and discuss where bispecific antibodies may fit in the treatment landscape. This discussion took place at the 5th International Workshop on CAR-T (iwCAR-T) 2023 held in Scottsdale, AZ.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
